As Korean biopharma firms, particularly bioventures, are suffering from a sharp decline in financing and licensing deals, the role of the state-supported Korea Drug Development Fund (KDDF) is becoming increasingly crucial to assist their R&D and business development activities and help weather the tough environment.
The KDDF was created in 2011, modelled after overseas agencies such as the US National Institutes of Health. The Korean...







